Replimune Group Consensus Price Target Increased by 29.5% to $19.55
The average one-year price target for Replimune Group (NASDAQGS:REPL) has been revised to $19.55 / share. This is an increase of 29.50% from the prior estimate of $15.10 dated August 25, 2026. These figures represent the aggregate target of multiple analysts and do not constitute a recommendation by Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $14.14 to a high of $25.20 / share. The average price target represents an increase of 49.12% from the latest reported closing price of $13.11 / share as of September 14, 2026.
This revision marks the fourth consecutive increase in the target, which has risen from $6.91 on June 30, 2026, to $10.82 on August 4, 2026, and $15.10 on August 28, 2026, before reaching the current $19.55 on September 15, 2026. The target has changed by +301.54% since the 90-day baseline date of June 8, 2026, when the target was at its observed twelve-month low mean of $4.87. The observed twelve-month high mean of $19.55 was recorded on September 15, 2026.
Replimune Group, Inc. is a biotechnology firm based in the United States, specializing primarily in the development of oncolytic immuno-gene therapies, including its key project RP1. In its latest earnings report on August 14, 2026, the company reported an actual EPS of -0.72, compared to the estimated EPS of -0.7324. Actual revenue was $0.00, compared to the estimated revenue of $204,000.00, representing a revenue surprise of -100.00%.
As of September 14, 2026, the stock's latest close of $13.11 reflects a one-week price change of -12.83% from a baseline close of $15.04 on September 4, 2026, and a one-month price change of -12.42% from a baseline close of $14.97 on August 14, 2026.
As of September 1, 2026, the recommendation breakdown consists of 5 strong buy, 7 buy, 1 hold, and 1 sell recommendations. This is a shift from August 1, 2026, when there were 4 strong buy, 7 buy, 2 hold, and 1 sell recommendations. Additionally, JP Morgan maintained an Overweight rating on the stock on August 26, 2026.
Within the Building Products sub-industry, 10 covered companies saw raised targets, 4 were lowered, and 20 remained unchanged, with a median revision percent of 0.00% and a median implied change percent of +47.63%.
Among its peers, target revisions remained flat or slightly positive, while implied changes ranged from +171.46% to +338.50%.
| Company | Target revision | Implied change |
|---|---|---|
| Cellectis S.A. - Depositary Receipt | +0.59% | +326.39% |
| Greenwich LifeSciences | 0.00% | +338.50% |
| Taysha Gene Therapies | 0.00% | +171.46% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.